| Literature DB >> 26664923 |
Jonathan B Clayton1, Jessica L Danzeisen1, Ava M Trent2, Tami Murphy3, Timothy J Johnson1.
Abstract
The gastrointestinal (GI) tracts of non-human primates (NHPs) are well known to harbor Escherichia coli, a known commensal of human beings and animals. While E. coli is a normal inhabitant of the mammalian gut, it also exists in a number of pathogenic forms or pathotypes, including those with predisposition for the GI tract as well as the urogenital tract. Diarrhea in captive NHPs has long been a problem in both zoo settings and research colonies, including the Como Zoo. It is an animal welfare concern, as well as a public health concern. E. coli has not been extensively studied; therefore, a study was performed during the summer of 2009 in collaboration with a zoo in Saint Paul, MN, which was previously experiencing an increased incidence and severity of diarrhea among their NHP collection. Fresh fecal samples were collected weekly from each member of the primate collection, between June and August of 2009, and E. coli were isolated. A total of 33 individuals were included in the study, representing eight species. E. coli isolates were examined for their genetic relatedness, phylogenetic relationships, plasmid replicon types, virulence gene profiles, and antimicrobial susceptibility profiles. A number of isolates were identified containing virulence genes commonly found in several different E. coli pathotypes, and there was evidence of clonal transmission of isolates between animals and over time. Overall, the manifestation of chronic diarrhea in the Como Zoo primate collection is a complex problem whose solution will require regular screening for microbial agents and consideration of environmental causes. This study provides some insight toward the sharing of enteric bacteria between such animals.Entities:
Keywords: Escherichia coli; antibiotic resistance; non-human primate; plasmid; virulence
Year: 2014 PMID: 26664923 PMCID: PMC4668849 DOI: 10.3389/fvets.2014.00024
Source DB: PubMed Journal: Front Vet Sci ISSN: 2297-1769
Primate populations included in this study.
| Animal ID | Common name | Scientific name | Sex | Age (years, as of 2009) |
|---|---|---|---|---|
| WLG1 | Western lowland gorilla | Male | 24 | |
| WLG2 | Western lowland gorilla | Male | 23 | |
| WLG3 | Western lowland gorilla | Male | 21 | |
| O1 | Orangutan | Female | 33 | |
| O2 | Orangutan | Male | 24 | |
| O3 | Orangutan | Female | 22 | |
| O4 | Orangutan | Male | 2 | |
| DM1 | De Brazza’s monkey | Female | 12 | |
| DM2 | De Brazza’s monkey | Male | 11 | |
| BHSM1 | Black-handed spider monkey | Male | 19 | |
| BHSM2 | Black-handed spider monkey | Male | 18 | |
| BHSM3 | Black-handed spider monkey | Female | 18 | |
| BHSM4 | Black-handed spider monkey | Female | 18 | |
| BHSM5 | Black-handed spider monkey | Female | 13 | |
| WFS1 | White-faced saki | Male | 9 | |
| WFS2 | White-faced saki | Female | 11 | |
| WFS3 | White-faced saki | Male | 4 | |
| WFS4 | White-faced saki | Male | 3 | |
| WFS5 | White-faced saki | Female | 1 | |
| BEBL1 | Blue-eyed black lemur | Male | 15 | |
| BEBL2 | Blue-eyed black lemur | Female | 12 | |
| ET1 | Emperor tamarin | Male | 21 | |
| ET2 | Emperor tamarin | Female | 11 | |
| ET3 | Emperor tamarin | Male | 2 | |
| ET4 | Emperor tamarin | Female | 2 | |
| ET5 | Emperor tamarin | Male | 2 | |
| ET6 | Emperor tamarin | Male | 2 | |
| ET7 | Emperor tamarin | Male | 17 | |
| ET8 | Emperor tamarin | Female | 12 | |
| ET9 | Emperor tamarin | Male | 3 | |
| ET10 | Emperor tamarin | Male | 3 | |
| GT1 | Geoffroy’s tamarin | Male | 12 | |
| GT2 | Geoffroy’s tamarin | Female | 9 |
G.: Gorilla; P.: Pongo; C.: Cercopithecus; A.: Ateles; P.: Pithecia; E.: Eulemur; S.: Saguinus.
Figure 1Results of resistance phenotyping, plasmid replicon analysis, virulence genotyping, and . Species are colored as follows: orange: De Brazza’s monkey; light pink: orangutan; pink: emperor tamarin; dark purple: spider monkey; light purple: white-faced saki; light green: lemur; dark green: gorilla; and light blue: Geoffroy’s tamarin. Dendrogram depicts relationships of isolates using fumC sequence analysis.
Overall prevalence of each gene and plasmid replicon studied (at least one positive isolate).
| Gene/Replicon | Prevalence (%) ( |
|---|---|
| IncP-1α | 6.8 ( |
| IncFIC | 8.0 ( |
| IncB/O | 3.7 ( |
| IncK/B | 2.5 ( |
| IncW | 0.6 ( |
| IncFIA | 3.1 ( |
| IncFIB | 25.3 ( |
| IncI1 | 14.2 ( |
| IncN | 1.2 ( |
| 7.4 ( | |
| 1.9 ( | |
| 19.8 ( | |
| 8.6 ( | |
| 17.3 ( | |
| 8.0 ( | |
| 1.9 ( | |
| 10.5 ( | |
| 8.0 ( | |
| 1.9 ( | |
| 13.0 ( | |
| 8.0 ( | |
| 9.3 ( | |
| 0.6 ( | |
| 0.6 ( | |
| 9.3 ( | |
| 4.9 ( | |
| 2.5 ( | |
| 10.5 ( | |
| 1.2 ( |
Prevalence of each gene and plasmid replicon studied by primate species.
| Gene/Replicon | Gorilla | Orangutan | De Brazza’s Monkey | Spider Monkey | White-faced Saki | Lemur | Emperor Tamarin | Geoffroy’s Tamarin |
|---|---|---|---|---|---|---|---|---|
| IncP-1α | 10.5% (2) | 14.8% (4) | 0.0% (0) | 0.0% (0) | 11.1% (3) | 0.0% (0) | 6.5% (2) | 0.0% (0) |
| IncFIC | 5.3% (1) | 0.0% (0) | 16.7% (2) | 0.0% (0) | 18.5% (5) | 20.0% (1) | 16.1% (5) | 0.0% (0) |
| IncB/O | 5.3% (1) | 0.0% (0) | 0.0% (0) | 2.9% (1) | 7.4% (2) | 0.0% (0) | 6.5% (2) | 0.0% (0) |
| IncK/B | 10.5% (2) | 3.7% (1) | 0.0% (0) | 2.9% (1) | 0.0% (0) | 0.0% (0) | 0.0% (0) | 0.0% (0) |
| IncW | 0.0% (0) | 0.0% (0) | 0.0% (0) | 0.0% (0) | 0.0% (0) | 0.0% (0) | 3.2% (1) | 0.0% (0) |
| IncFIA | 0.0% (0) | 0.0% (0) | 0.0% (0) | 0.0% (0) | 14.8% (4) | 20.0% (1) | 0.0% (0) | 0.0% (0) |
| IncFIB | 21.1% (4) | 37.0% (10) | 0.0% (0) | 17.6% (6) | 48.1% (13) | 40.0% (2) | 9.7% (3) | 42.9% (3) |
| IncI1 | 0.0% (0) | 0.0% (0) | 33.3% (4) | 44.1% (15) | 11.1% (3) | 0.0% (0) | 9.7% (3) | 0.0% (0) |
| IncN | 5.3% (1) | 3.7% (1) | 0.0% (0) | 0.0% (0) | 0.0% (0) | 0.0% (0) | 0.0% (0) | 0.0% (0) |
| 47.4% (9) | 3.7% (1) | 0.0% (0) | 2.9% (1) | 0.0% (0) | 0.0% (0) | 3.2% (1) | 0.0% (0) | |
| 0.0% (0) | 0.0% (0) | 0.0% (0) | 0.0% (0) | 0.0% (0) | 0.0% (0) | 9.7% (3) | 0.0% (0) | |
| 57.9% (11) | 22.2% (6) | 8.3% (1) | 14.7% (5) | 7.4% (2) | 0.0% (0) | 12.9% (4) | 42.9% (3) | |
| 0.0% (0) | 33.3% (9) | 0.0% (0) | 0.0% (0) | 3.7% (1) | 20.0% (1) | 0.0% (0) | 42.9% (3) | |
| 57.9% (11) | 37.0% (10) | 0.0% (0) | 0.0% (0) | 7.4% (2) | 20.0% (1) | 9.7% (3) | 28.6% (2) | |
| 5.3% (1) | 33.3% (9) | 0.0% (0) | 0.0% (0) | 7.4% (2) | 20.0% (1) | 0.0% (0) | 0.0% (0) | |
| 0.0% (0) | 7.4% (2) | 0.0% (0) | 0.0% (0) | 0.0% (0) | 0.0% (0) | 0.0% (0) | 14.3% (1) | |
| 5.3% (1) | 25.9% (7) | 0.0% (0) | 2.9% (1) | 14.8% (4) | 20.0% (1) | 3.2% (1) | 28.6% (2) | |
| 36.8% (7) | 0.0% (0) | 0.0% (0) | 2.9% (1) | 14.8% (4) | 0.0% (0) | 3.2% (1) | 0.0% (0) | |
| 0.0% (0) | 0.0% (0) | 0.0% (0) | 0.0% (0) | 0.0% (0) | 0.0% (0) | 9.7% (3) | 0.0% (0) | |
| 0.0% (0) | 0.0% (0) | 25.0% (3) | 11.8% (4) | 11.1% (3) | 20.0% (1) | 29.0% (9) | 28.6% (2) | |
| 0.0% (0) | 0.0% (0) | 25.0% (3) | 0.0% (0) | 3.7% (1) | 20.0% (1) | 29.0% (9) | 0.0% (0) | |
| 0.0% (0) | 0.0% (0) | 25.0% (3) | 8.8% (3) | 3.7% (1) | 20.0% (1) | 25.8% (8) | 0.0% (0) | |
| 0.0% (0) | 0.0% (0) | 0.0% (0) | 0.0% (0) | 0.0% (0) | 0.0% (0) | 3.2% (1) | 0.0% (0) | |
| 0.0% (0) | 0.0% (0) | 8.3% (1) | 0.0% (0) | 0.0% (0) | 0.0% (0) | 0.0% (0) | 0.0% (0) | |
| 31.6% (6) | 0.0% (0) | 0.0% (0) | 5.9% (2) | 18.5% (5) | 0.0% (0) | 6.5% (2) | 0.0% (0) | |
| 0.0% (0) | 0.0% (0) | 25.0% (3) | 2.9% (1) | 11.1% (3) | 0.0% (0) | 6.5% (2) | 0.0% (0) | |
| 0.0% (0) | 0.0% (0) | 0.0% (0) | 8.8% (3) | 3.7% (1) | 0.0% (0) | 0.0% (0) | 0.0% (0) | |
| 0.0% (0) | 0.0% (0) | 25.0% (3) | 5.9% (2) | 18.5% (5) | 20.0% (1) | 22.6% (7) | 0.0% (0) | |
| 0.0% (0) | 0.0% (0) | 16.7% (2) | 0.0% (0) | 0.0% (0) | 0.0% (0) | 3.2% (1) | 0.0% (0) | |
Prevalence of gene and plasmid replicon among the whole population over time.
| Gene/Replicon | Week 1 | Week 2 | Week 3 | Week 4 | Week 5 | Week 6 | Week 7 |
|---|---|---|---|---|---|---|---|
| IncP-1α | 0.0% (0) | 0.0% (0) | 20.8% (5) | 0.0% (0) | 26.1% (6) | 0.0% (0) | 0.0% (0) |
| IncFIC | 5.0% (1) | 4.8% (1) | 8.3% (2) | 18.2% (4) | 8.7% (2) | 3.2% (1) | 9.5% (2) |
| IncB/O | 0.0% (0) | 0.0% (0) | 20.8% (5) | 0.0% (0) | 4.3% (1) | 0.0% (0) | 0.0% (0) |
| IncK/B | 0.0% (0) | 0.0% (0) | 4.2% (1) | 0.0% (0) | 13.0% (3) | 0.0% (0) | 0.0% (0) |
| IncW | 5.0% (1) | 0.0% (0) | 0.0% (0) | 0.0% (0) | 0.0% (0) | 0.0% (0) | 0.0% (0) |
| IncFIA | 0.0% (0) | 4.8% (1) | 4.2% (1) | 9.1% (2) | 0.0% (0) | 3.2% (1) | 0.0% (0) |
| IncFIB | 10.0% (2) | 42.9% (9) | 33.3% (8) | 59.1% (13) | 17.4% (4) | 12.9% (4) | 4.8% (1) |
| IncI1 | 15.0% (3) | 4.8% (1) | 12.5% (3) | 13.6% (3) | 30.4% (7) | 9.7% (3) | 14.3% (3) |
| IncN | 0.0% (0) | 0.0% (0) | 4.2% (1) | 0.0% (0) | 4.3% (1) | 0.0% (0) | 0.0% (0) |
| 0.0% (0) | 14.3% (3) | 16.7% (4) | 4.5% (1) | 8.7% (2) | 6.5% (2) | 0.0% (0) | |
| 0.0% (0) | 4.8% (1) | 4.2% (1) | 4.5% (1) | 0.0% (0) | 0.0% (0) | 0.0% (0) | |
| 10.0% (2) | 28.6% (6) | 29.2% (7) | 18.2% (4) | 13.0% (3) | 12.9% (4) | 28.6% (6) | |
| 0.0% (0) | 19.0% (4) | 8.3% (2) | 18.2% (4) | 8.7% (2) | 6.5% (2) | 0.0% (0) | |
| 20.0% (4) | 28.6% (6) | 20.8% (5) | 22.7% (5) | 17.4% (4) | 12.9% (4) | 4.8% (1) | |
| 5.0% (1) | 14.3% (3) | 8.3% (2) | 9.1% (2) | 8.7% (2) | 6.5% (2) | 4.8% (1) | |
| 0.0% (0) | 4.8% (1) | 0.0% (0) | 9.1% (2) | 0.0% (0) | 0.0% (0) | 0.0% (0) | |
| 5.0% (1) | 14.3% (3) | 12.5% (3) | 22.7% (5) | 8.7% (2) | 6.5% (2) | 4.8% (1) | |
| 5.0% (1) | 19.0% (4) | 12.5% (3) | 4.5% (1) | 8.7% (2) | 3.2% (1) | 4.8% (1) | |
| 0.0% (0) | 4.8% (1) | 4.2% (1) | 4.5% (1) | 0.0% (0) | 0.0% (0) | 0.0% (0) | |
| 20.0% (4) | 4.8% (1) | 16.7% (4) | 9.1% (2) | 17.4% (4) | 3.2% (1) | 23.8% (5) | |
| 25.0% (5) | 0.0% (0) | 12.5% (3) | 0.0% (0) | 13.0% (3) | 3.2% (1) | 4.8% (1) | |
| 15.0% (3) | 0.0% (0) | 16.7% (4) | 9.1% (2) | 17.4% (4) | 3.2% (1) | 4.8% (1) | |
| 5.0% (1) | 0.0% (0) | 0.0% (0) | 0.0% (0) | 0.0% (0) | 0.0% (0) | 0.0% (0) | |
| 0.0% (0) | 4.8% (1) | 0.0% (0) | 0.0% (0) | 0.0% (0) | 0.0% (0) | 0.0% (0) | |
| 5.0% (1) | 14.3% (3) | 16.7% (4) | 18.2% (4) | 8.7% (2) | 3.2% (1) | 0.0% (0) | |
| 5.0% (1) | 4.8% (1) | 8.3% (2) | 0.0% (0) | 4.3% (1) | 9.7% (3) | 0.0% (0) | |
| 0.0% (0) | 4.8% (1) | 4.2% (1) | 9.1% (2) | 0.0% (0) | 0.0% (0) | 0.0% (0) | |
| 10.0% (2) | 9.5% (2) | 16.7% (4) | 13.6% (3) | 17.4% (4) | 3.2% (1) | 4.8% (1) | |
| 0.0% (0) | 0.0% (0) | 0.0% (0) | 0.0% (0) | 8.7% (2) | 0.0% (0) | 0.0% (0) | |
Prevalence of antibiotic resistance by primate species (.
| Antibiotic | Gorilla | Orangutan | De Brazza’s Monkey | Spider Monkey | White-faced Saki | Lemur | Emperor tamarin | Geoffroy’s tamarin |
|---|---|---|---|---|---|---|---|---|
| Ampicillin | 10.5% (2) | 11.1% (3) | 33.3% (4) | 5.9% (2) | 29.6% (8) | 0.0% (0) | 32.3% (10) | 0.0% (0) |
| Gentamycin | 0.0% (0) | 0.0% (0) | 8.3% (1) | 0.0% (0) | 0.0% (0) | 0.0% (0) | 0.0% (0) | 0.0% (0) |
| Nalidixic acid | 0.0% (0) | 0.0% (0) | 0.0% (0) | 0.0% (0) | 0.0% (0) | 0.0% (0) | 0.0% (0) | 0.0% (0) |
| Streptomycin | 0.0% (0) | 0.0% (0) | 0.0% (0) | 5.9% (2) | 18.5% (5) | 0.0% (0) | 6.5% (2) | 0.0% (0) |
| Tetracycline | 0.0% (0) | 0.0% (0) | 8.3% (1) | 8.8% (3) | 22.2% (6) | 0.0% (0) | 41.9% (13) | 0.0% (0) |
| Sulfisoxazole | 5.3% (1) | 3.7% (1) | 0.0% (0) | 5.9% (2) | 22.2% (6) | 20.0% (1) | 6.5% (2) | 0.0% (0) |
| Trimethoprim | 0.0% (0) | 3.7% (1) | 0.0% (0) | 5.9% (2) | 11.1% (3) | 0.0% (0) | 6.5% (2) | 0.0% (0) |
Figure 2Map of Como Zoo’s primate enclosure locations, including those in holding and on-exhibit. Species are colored as follows: gray = gorilla, orange = orangutan, purple = De Brazza’s monkey, yellow = spider monkey, blue = lemur, green = Emperor tamarin, and red = white-faced saki and Geoffroy’s tamarin.